expressed at higher level in primate cerebral cortex than mouse cerebral cortex and what's more, periostin exhibited neurite outgrowth activity. 15 Periostin was observed in neurons and increased in astrocytes at 24 hours after transient middle cerebral artery occlusion (tMCAo), which indicated that periostin might play an important role in the pathologic process after stroke. 16 Recently, study showed that serum periostin concentrations in patients with traumatic brain injury (TBI) was significantly higher than healthy individuals and level of periostin was significantly associated with clinical severity. 17 While in SAH mouse model, periostin neutralization could alleviate EBI. 1 μg r-periostin could significantly aggravated brain edema after SAH, 18 which indicated that periostin may play a important role in pathologic process after SAH. While no study has revealed the role of serum periostin in patients with aSAH till now. So we performed this study to explore the role of periostin in patients with aSAH.
| METHOD

| Study population
This was retrospective study and all included patients were treated in the department of neurosurgery of Shenzhen People's hospital during March 1st 2015 to December 30th 2016. Patients were diagnosed as aneurysmal subarachnoid hemorrhage by head computed tomography (CT) and further confirmed by subsequent head CT angiography (CTA) or digital subtraction angiography (DSA). We excluded patients whose blood sample collection was more than 72 hours from symptom onset. Patients who were accompanied with infectious diseases, autoimmune disease or serve organ dysfunction 2 weeks before hospitalization and those who had history of neurological diseases were also excluded. All included patients received standard treatments which included hemostasis, reduce cerebral edema, prophylactic antiseizure and anti-vasospasm before surgery. All participants or their relatives were informed and an consent was written for each patients. Our study was approved by the ethical committee at Shenzhen
People's hospital.
| Clinical assessment
Baseline information (sex, gender, comorbidities, etc.) of patients included were collected. Neurological assessment was conducted by using Glasgow Coma scale (GCS) and hunt-hess grade. Fisher grade was accessed for each patients based on the presentation of head CT on admission. Head CT was routinely performed for all patients on the first day and at any time during hospital stay if patients suffered clinical deterioration. Delayed cerebral ischemia (DCI) was defined as previous described. 19 All 12-month follow-up was performed by using telephone interviews and poor outcome was defined as Glasgow outcome scale (GOS) score 1-3 and good outcome was defined as GOS score 4-5.
| Blood samples measurements
Two milliliters of blood samples were collected in early morning and immediately centrifuged at 2000 g for 15 minutes at −4°C. The serum was collected and stored at −80°C. Human Periostin ELISA Kit (RAB1075, SIGMA) was used to detect serum level of periostin according to the manufacture's instruction.
| Statistical analysis
The descriptive analysis (mean, standard deviation, median) was used for continuous variables and percentage for categorical variables. t test or One-Way ANOVA analysis was used for the comparisons between groups for continuous variables. Box-plot was used to present levels of periostin between different groups. In order to assess the risk factors of poor outcome, variables were first analyzed by performing univariate logistic regression analysis and then multivariate logistic regression analysis would be used to analyzed the factors with P < .1. Receiver operating characteristic (ROC) curves were used to accessed the variables' prediction ability. Statistical analyses were conducted by using SPSS 21.
| RESULTS
| Baseline information
Finally, there were 124 patients with aSAH included in this study.
There were 78 females and 46 males with an overall average age of 
| Level of periostin correlated with clinical severity
Correlation analysis revealed that periostin was significantly corre- 
| Serum periostin concentrations in aSAH patients
There were 12 patients suffered with DCI during hospital stay and patients with DCI had higher level of serum periostin than those with non-DCI (343.75 ± 64.65 vs 211.32 ± 112.04, P < .01). Figure 2 .
Besides, level of periostin was elevated in patients with poor outcome at 12 month than patients with good outcome (328.48 ± 121.40 vs 186.30 ± 85.69, P < .01).
| Prognostic effect of periostin on poor outcome
Multivariate regression analysis were used to analyze risk factors associated with poor outcome of patients with aSAH after using univariate analysis. The results showed that current smoking, DCI, high grade
Fisher grade (III-IV) and elevated level of periostin were significantly associated with poor outcome. Results of the mutivariate analyses are shown in Table 2 . Besides, we also performed multivariate logistic regression analysis of occurrence of DCI and the results showed high serum concertration of periostin was an independent risk factor of DCI. Results were presented in Table 3 . ROC was used to accessed the value of periostin in predicting poor outcome. The AUC of periostin, Hunt-hess grade and Fisher grade in predicting poor outcome was 0.85, 0.73, 0.70, respectively, which indicated that periostin was an good diagnostic role in predicting poor outcome of aSAH patients ( Figure 3 and Table 4 ).
| DISCUSSION
Periostin is a extracellular matric protein which haven't been investigated in aSAH. In this retrospective study, we found that patients with poor oucome had higher level of periostin than patients with good outcome at 12 months. Level of periostin was negatively cor- 
T A B L E 4 Diagnostic value of variables for poor outcome of aSAH patients
Previous studies have identified periostin was involved in process of inflammation, oxidative stress and it played a key role in promoting tumor progression under hypoxia. Periostin have been investigated as a biomarker in various diseases. Periostin was found to plays an important role in repairing the biological matrix of the lung and serum periostin can predict clinical progression both in asthma and idiopathic pulmonary fibrosis. 20 Besides, periostin was found to involve in the progression of cancer and metastatic processes, as well as acting an regulator of epithelial mesenchymal transition (EMT). 21 Serum periostin was elevated in patient with advanced non-samll cell lung cancer and could be used as an reliable marker to predict patients' chemotherapy response and survival. 22 Few studies have explored the role of periostin in neurological diseases till now. Matsunaga et al reported that periostin was expressed at higher level in primate cerebral cortex than mouse cerebral cortex and periostin exhibited neurite outgrowth activity in brain tissues. 15 Recent studies have revealed that periostin was overexpressed in neural stem cell (NSCs) following hypoxia ischemia and hypoxia could increased periostin expression. 13, 23 Hypoxia, oxidative stress and inflammatory reaction could be involved in the pathological processes of traumatic brain injury (TBI) 24 and stroke, 25 so periostin was supposed to elevated in these neurological diseases.
Periostin1 and periostin2 (its splicing variant) were both investigated in transient middle cerebral artery occlusion (tMCAo) model. The results showed that periostin 2, not periostin 1 was overexpressed at 24 hours after tMCAo. Exogenously injection of periostin 2 could reduce infarct volume, which indicated that periostin 2 exhibit antihypoxia property and an protective effect. 16 While on the contrary, previous study found that periostin was higher expressed in heart failure and inhibited expression of periostin could increase survival rate, which indicated that inhibition of periostin might be a potential theraphy for heart failure. 26 Another study conducted by Xiao-Qiao Dong et al revealed its role in traumatic brain injury. Serum periostin in patients with TBI was higher than patients in control group and level of periostin was significantly correlated with GCS. Our study showed similar results to this report. Patients who had DCI during hospital stay had higher level of periostin and periostin concentration was negatively correlated with GCS. While AUC of periostin in predicting 30-day mortality of patients with TBI was 0.815. Periostin might play different role in pathological procession of TBI and SAH. Previous study demonstrated that anti-periostin antibody could prevented post-SAH neurobehavioral impariments and EBI. Recombinant-periostin significantly aggravated EBI. 18 However, serum periostin in patients with SAH hadn't been investigated yet and it was still unknown if periostin could be used as a prognostic biomarker in SAH. This was the first study to explored the role of periostin in patients with SAH. We found periostin was highly expressed in patients with poor outcome. Besides. AUC of periostin was 0.850 in predicting poor outcome at 12 months. Our study proved that perisotin could be used as a prognostic biomarker in patient with SAH.
There were some limitations in this retrospective study. Patients included in this study was relatively small and patients received both clipping and coiling were enrolled, which may caused extra biases because of different brain trauma caused by clipping and coiling. Besides, blood samples were routinely collected in the first morning and patients might treated with certain amount of liquid, which might have some effect on the level of serum periostin. Finally, in this study, we only explored preoperative level of periostin in patients with SAH and dynamic change of serum of periostin haven't been investigated till now.
In conclusion, aSAH patients with poor oucome had higher level of periostin than patients with good outcome at 12 months. Serum periostin was significantly correlated with GCS, Hunt-hess grade and Fisher grade. AUC was 0.850 of periostin in predicting poor outcome at 12 months which indicated that periostin could be used as a prognostic biomarker in patients with aSAH.
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